- Title: Subtitle
- FP03.05 TLR9 Agonist CMP-001 Plus Atezolizumab +/- Radiation Therapy in Patients With PD-1 Blockade Resistant Advanced NSCLC
- Creators
- M. Negrao - The University of Texas MD Anderson Cancer CenterV. Papadimitrakopoulou - The University of Texas MD Anderson Cancer CenterA.C. Price - Banner MD Anderson Cancer Center, Gilbert/AZ/USA.L. Tam - The University of Texas MD Anderson Cancer CenterM. Furqan - University of IowaS.T. Laroia - University of IowaE. Massarelli - City of Hope, Duarte/CA/USJ. Pacheco - University of Colorado Cancer CenterJ.V. Heymach - The University of Texas MD Anderson Cancer CenterA.S. Tsao - The University of Texas MD Anderson Cancer CenterG. Walker - Banner MD Anderson Cancer Center, Gilbert/AZ/USL. Vora - City of Hope, Duarte/CA/USD. Mauro - Checkmate Pharmaceuticals, Inc., Cambridge/MA/USH. Kelley - Checkmate Pharmaceuticals, Inc., Cambridge/MA/USJ.E. Woolridge - Checkmate Pharmaceuticals, Inc., Cambridge/MA/USA.M. Krieg - Checkmate Pharmaceuticals, Inc., Cambridge/MA/USJ. Niu - Banner MD Anderson Cancer Center, Gilbert/AZ/US
- Resource Type
- Abstract
- Publication Details
- Journal of thoracic oncology, Vol.16(3), pp.S196-S196
- DOI
- 10.1016/j.jtho.2021.01.087
- ISSN
- 1556-0864
- eISSN
- 1556-1380
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 03/2021
- Academic Unit
- Radiology; Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984320089602771
Abstract
FP03.05 TLR9 Agonist CMP-001 Plus Atezolizumab +/- Radiation Therapy in Patients With PD-1 Blockade Resistant Advanced NSCLC
Journal of thoracic oncology, Vol.16(3), pp.S196-S196
03/2021
DOI: 10.1016/j.jtho.2021.01.087
Details
Metrics
12 Record Views